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Germinal centres (GCs) are specialised lymphoid
microenvironments that form in secondary B-cell
follicles upon exposure to T-dependent antigens. In
the GC, clonal expansion, selection and differentiation
of GC B cells result in the production of high-affinity
plasma cells and memory B cells that provide protection
against subsequent infection. The GC is carefully
regulated to fulfil its critical role in defence against
infection and to ensure that immunological tolerance
is not broken in the process. The GC response can be
controlled by a number of mechanisms, one of which
is by forkhead box p3 expressing regulatory T (Treg)
cells, a suppressive population of CD4+ T cells. A
specialised subset of Treg cells – follicular regulatory
T (Tfr) cells – form after immunisation and are able
to access the GC, where they control the size and
output of the response. Our knowledge of Treg cell
control of the GC is expanding. In this review we will
discuss recent advances in the field, with a particular
emphasis on the differentiation and function of Tfr
cells in the GC.lar antibody response or enter the B-cell follicle to seed
the GC [10].Introduction
The establishment of antigen-specific memory responses
is a key aspect of adaptive immunity that protects the host
against future infections and forms the basis of successful
immunisation. Germinal centres (GCs) are specialised mi-
croenvironments that form in B-cell follicles within sec-
ondary lymphoid organs upon infection or immunisation
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ing cells and memory B cells [1].
The GC response is initiated when B cells encounter
antigen within the secondary lymphoid tissues. Naïve B
cells recirculate through secondary lymphoid tissues and
enter the B-cell follicle, located underneath the subcapsu-
lar sinus in the lymph nodes and underneath the marginal
zone in the spleen, near sites of antigen entry [2]. In the
follicle, naïve B cells scan for their specific antigen and are
activated following engagement of their B-cell receptor
(BCR) by small soluble antigens directly, by antigen pres-
entation from subcapsular sinus macrophages [3-5], or by
taking up antigen from follicular dendritic cells (FDC) [6].
After antigen encounter, B cells rapidly upregulate C-C
chemokine receptor type 7 (CCR7), whose ligands chemo-
kine (C-C motif) ligand (CCL)21 and CCL19 are expressed
in the adjacent T-cell zone. B cells use this gradient to mi-
grate towards the T:B border, where they engage in cognate
interactions with CD4+ T-helper type (Th) cells [7]. B cells
then upregulate the orphan G protein-coupled receptor
Epstein–Barr virus-induced gene 2 (EBI2), allowing the
B cell to migrate to the outer edges of the follicle [8,9].
After division, B cells either take part in the extrafollicu-
B cells that differentiate into extrafollicular plasma cells
secrete class-switched or non-class-switched antibodies in
the early phase of infection and undergo apoptosis in situ
after a few days [11]. This initial and rapid burst of anti-
body production is an important component of the early
immune response against infectious organisms and allows
time for the GC to mature without compromising host de-
fence during this time [12].
B cells that enter the B-cell follicle to seed the GC begin
to divide rapidly, and after this initial clonal expansion the
GC divides into two distinct zones: the dark zone and the
light zone. In the dark zone, B-cell clones undergo somatic
hypermutation, which introduces random point mutations
in the V regions of their immunoglobulin genes [13]. This
process is followed by affinity-based selection in the lightentral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
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follicular helper T (Tfh) cells. B cells with somatically mu-
tated BCRs collect antigen from the surface of FDC, in-
ternalise it and present it to Tfh cells in the context of
major histocompatibility complex class II (MHC-II). B
cells with the highest affinity BCRs are able to outcompete
lower affinity B cells for T-cell help, resulting in further
clonal expansion of high-affinity GC B cells and formation
of high-affinity plasma cells and memory B cells [14,15].
This process of mutation and selection that generates ef-
fector B cells with BCRs with increased affinity for antigen
is referred to as affinity maturation, and competition for
Tfh cell help is an essential mediator of this [15].
Follicular helper T cells
Tfh cells are essential for the formation and maintenance
of the GC response [16]. Tfh differentiation is initiated by
priming of the CD4+ T cell by dendritic cells (DCs) via the
engagement of the T-cell receptor (TCR) by the MHC-II
peptide complex on DCs in conjunction with co-
stimulation between CD80/CD86 on the DC and CD28
on the T cell. During these T:DC interactions, the cyto-
kines IL-6 and IL-12 and the co-stimulatory molecule in-
ducible co-stimulator (ICOS) support differentiation into
Tfh precursor cells [17]. These signals are critical for in-
duction of the transcription factor B-cell lymphoma (Bcl)-
6 [18], which is both necessary and sufficient for Tfh
differentiation [19-21]. Bcl-6 promotes Tfh differentiation
by actively repressing the Th1 (Tbet), Th2 (GATA-bind-
ing-protein 3 (GATA3)), Th17 (retinoid-orphan receptor
gamma (RORγt)) and regulatory T (Treg) (forkhead box
p3 (Foxp3)) master transcription factors as well as the
transcription factor B-lymphocyte-induced maturation
protein 1 (Blimp-1) [19-21]. Bcl-6 and Blimp-1 are mutu-
ally antagonistic and the balance of these two transcription
factors is essential for optimal Tfh cell differentiation [21].
Expression of CXCR5 allows T cells to migrate to the
T:B border towards the ligand for CXCR5, CXCL13,
which is expressed by FDC in the follicle [22,23]. Induc-
tion of CXCR5 on Tfh precursor cells is mediated by the
expression of the transcription factor achaete-scute com-
plex homolog 2 (Ascl-2) [24]. After T-cell priming, Tfh
precursor cells need to interact with B cells in order to
fully differentiate into GC Tfh cells; these stable interac-
tions between Tfh precursor cells and B cells are medi-
ated by ligation of the SLAM family of receptors, CD84
and Ly108, supported by the intracellular adaptor mol-
ecule SLAM-associated protein (SAP) [25]. Tfh cells also
receive signals through ICOS during interactions with
bystander B cells; this induces the phosphatidylinositide
3-kinase pathway and triggers actin waves and polarised
pseudopod formation, facilitating the migration of Tfh
cells to the follicle [26]. Once within the GC, Tfh cells
provide help to GC B cells.Fully differentiated GC Tfh cells provide survival and
differentiation signals to GC B cells through CD40 lig-
and–CD40 interactions and secretion of cytokines, in-
cluding IL-21 and IL-4 [27-31]. GC B cells compete with
each other for help from Tfh cells by presenting antigen
on MHC-II. Those GC B cells that can engage Tfh cells
will receive survival and differentiation cues to exit the
GC as long-lived plasma cells or memory cells or to
undergo further rounds of somatic hypermutation. The
B cells with the highest affinity BCRs are able to collect
and then present the most antigen to Tfh cells, thereby
outcompeting the lower affinity B cells for T-cell help.
The dialogue between Tfh and GC B cells is not one dir-
ectional, with B cells providing signals to Tfh cells that
control their maintenance and function. PD-1 ligation
on Tfh cells during interaction with B cells controls the
Tfh cell number, and secretion of the cytokine IL-21 and
CD80 expression on B cells supports Tfh survival [32,33].
Together, the priming of naïve CD4+ T cells leads to spe-
cific changes in gene transcription that culminates in Tfh
differentiation and migration into the GC, where they pro-
vide essential help to GC B cells for their selection, sur-
vival and differentiation.
Control of the germinal centre by Foxp3+
regulatory T cells
Foxp3+ regulatory T cells
The size and specificity of the GC is influenced by
a number of factors such as antibody feedback [34],
Qa-1+CD8+ Treg cells [35] and Foxp3+ Treg cells. This
review will focus on the latter and their role in control-
ling the GC response. Foxp3+ Treg cells are a subset of
CD4+ T cells that suppress immune responses and are
essential for maintaining immunological tolerance [36].
Treg cells can develop in the thymus and these Foxp3+
cells are referred to as thymic Treg cells [37,38]. In
addition to thymic Treg cells, recent thymic emigrants
can switch on Foxp3 expression and become suppressive
Treg cells [39]. Treg cells originating from the thymus
have a TCR repertoire whose specificity is skewed towards
self-antigen and is distinct from that of conventional ef-
fector T cells [40]. Treg cells can also differentiate from
non-Treg CD4+ T cells that switch on Foxp3 expression in
the periphery; these are referred to as peripheral Treg cells
[41]. Finally, Treg cells can be generated in vitro in the
presence of transforming growth factor beta and are re-
ferred to as induced Treg cells [38].
The transcription factor Foxp3 is essential for the sup-
pressive function of Treg cells. In humans, mutations in
FOXP3 lead to immune dysregulation, polyendocrinopa-
thy, enteropathy, and X-linked syndrome (IPEX), which
is characterised by severe systemic autoimmunity. Simi-
larly, deficiency of Foxp3 in mice (scurfy mice) leads
to unrestrained T-cell and humoral immune responses,
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expansion in the absence of immunisation or infection
[42-44]. Mice in which Foxp3+ cells lack interferon regu-
latory factor (IRF)4 develop spontaneous GCs but are
not a phenocopy of Foxp3-deficient mice [45]. This ob-
servation suggests that IRF4 controls an aspect of Treg
biology that is essential for moderating the GC itself and
that specific, cell-intrinsic molecular pathways mediate
the suppression of the spontaneous GC response by
Treg cells. IRF4 is required for expression of the homing
molecules CD62L and CD103 and the inhibitory molecule
cytotoxic T-lymphocyte antigen 4 (CTLA-4), and changes
in these molecules may have implications for Treg control
of the GC. There is evidence that CTLA-4 is also a critical
regulator of the GC as CTLA-4-deficient mice develop
spontaneous GCs [46]. CTLA-4 is expressed at high levels
on Treg cells and exerts its inhibitory function by depleting
CD80/CD86 from the surface of antigen-presenting cells
by trans-endocytosis, thereby inhibiting co-stimulatory sig-
nalling [47]. This inhibition results in failure of DCs to ac-
tivate T cells through CD28, thereby inhibiting priming of
CD4+ T cells. Taken together, these findings demonstrate
that Foxp3+ Treg cells play a role in suppressing the initi-
ation of the GC, and CTLA-4 is a probable effector mech-
anism by which Treg cells may mediate this suppression. It
could be speculated that extrafollicular Treg cells suppress
GC initiation by means of CTLA-4-mediated inhibition of
T-cell proliferation and subsequent Tfh cell differentiation.
In contrast to the finding that Foxp3+ Treg cells sup-
press the GC response, Leon and colleagues demon-
strated that Treg cells can promote GC responses [48].
Using influenza infection in a strain of mice where treat-
ment with diphtheria toxin specifically eliminates all
Foxp3+ cells, they demonstrated that ablation of Treg
cells results in a decrease in antigen-specific GC B cells
[48]. In this model, Treg suppression of the GC was me-
diated by limiting the availability of IL-2. IL-2 signalling
negatively impacts on Tfh differentiation by upregulating
the transcription factor Blimp-1 in a signal transducer
and activator of transcription (STAT)5-dependent man-
ner [49,50], suggesting that when Treg cells are not able
to limit IL-2, primed T cells are skewed away from the
Tfh lineage due to increased IL-2 signalling. These data
seem to be in contrast to the data described above that
show that Foxp3+ Treg cells inhibit the GC response.
However, work from Wing and Sakaguchi demonstrated
that Treg cell control of the GC differs depending on
the time point of the response in which they are acting.
Depletion of Treg cells at the time of immunisation en-
hances the number of antigen-specific Tfh cells and GC
B cells, whereas depletion later in the response leads to
expansion of non antigen-specific GC B cells and Tfh
cells, at the expense of cells specific for the responding
antigen [46]. Consistent with this, Leon and colleaguesdepleted Treg cells on days 0, 4 and 7 relative to influ-
enza infection followed by analysis on day 10 [48]. These
time points are prior to the peak of the GC response fol-
lowing influenza infection [51], a time point during
which Treg cells promote the initiation of the immune
response by supporting effector CD4+ T-cell differenti-
ation rather than suppressing the GC response.
These data also suggest that there might be an import-
ant difference between Treg cells controlling the GC from
outside the follicle by controlling its initiation and follicu-
lar regulatory T (Tfr) cells controlling the GC from inside
where they regulate the size and output of the response.
Taken together, extrafollicular Treg cells may inhibit the
formation of a GC response in the absence of immunisa-
tion or infection via CTLA-4 trans-endocytosis. But these
cells may also enhance the initiation of the GC response
after infection by limiting IL-2 availability and thereby
promoting Tfh differentiation (Figure 1).
Follicular regulatory T cells
Tfr cells are a subset of Foxp3+ Treg cells that are found
within the GC, where they act to control the magnitude
and output of the GC response. Lim and colleagues first
identified Foxp3+ cells within human tonsil GCs in
2004 [52]. These authors demonstrated that addition of
CD4+CD25+CD69− T cells to co-cultures of CD57+ Th
cells with naïve, GC or memory B cells isolated from tonsils
suppressed antibody production. The CD4+CD25+CD69−
T-cell populations were shown to contain FOXP3-express-
ing cells. Although the authors suggest that some of these
cells can be identified in the GC, these CD4+CD25+CD69−
Treg cells highly express CCR7, whose ligands are not
expressed in the GC, and not CXCR5, the key migration
cue for access to the GC. Therefore, it is unlikely that these
CD4+CD25+CD69− Treg cells are all located within the GC
but they may control the response from outside the follicle.
Interestingly, activation of CD4+CD25+CD69− Treg cells
increased the expression of CXCR5, facilitating their mi-
gration towards CXCL13. This indicates that TCR activa-
tion is able to change the chemotactic profile of Treg cells
to facilitate migration into the GC. The CD69+ counter-
parts of these Treg cells do express CXCR5, and it could
be speculated that upon activation CD4+CD25+CD69−
Treg cells start to express CD69 and CXCR5 to migrate to
the GC. Following on from this work, in 2011 three inde-
pendent groups demonstrated that Foxp3+CD4+ T cells
are able to undergo functional differentiation into a spe-
cialised subset of Treg cells that migrate into the GC and
control its size and output directly [44,53,54]. These Treg
cells located inside the GC are now referred to as Tfr cells.
The origin of follicular regulatory T cells
Tfr cells are a distinct T-cell population within the GC
that phenotypically mirror Tfh cells in many aspects,
Figure 1 Extrafollicular Foxp3+ regulatory T cells control the initiation of the germinal centre response. (A) During the early germinal
centre (GC) response, Foxp3+ regulatory T (Treg) cells promote the immune response by IL-2 consumption. (B) A model of Foxp3+ Treg
cell-mediated GC suppression by cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 is able to trans-endocytose CD80/86 from the dendritic
cell (DC), thereby inhibiting co-stimulatory signalling through CD28 on the CD4+ T cells. Defective T-cell priming will result in failure of follicular
helper T (Tfh) cell differentiation. Foxp3, forkhead box p3; MHC-II, major histocompatibility complex class II; TCR, T-cell receptor.
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as Tfh lineage-specific transcription factor Bcl-6 along
with CXCR5, PD-1, ICOS, and SAP [44,53]. Tfr cells
do not express the B-cell helper molecules IL-21, IL-4
and CD40 ligand that are characteristic of Tfh cells [53].
Instead they express a range of typical Treg cell markers
in addition to Foxp3, such as glucocorticoid-induced
tumour necrosis factor receptor-related protein and
CTLA-4 [44,53]. Gene expression profile analysis further
showed that Tfr cells have a distinct transcriptional pro-
file that has more in common with Treg cells than Tfh
or other Th cells [53].
Because Tfr cells have phenotypic characteristics of
both Tfh and Treg cells, it seemed likely that these cells
arise from one or the other of these cell types. Thus, Tfr
cells could derive from Foxp3+ Treg cells that enter the
GC or from Tfh cells that switch on Foxp3 within the
GC. To determine the origin of Tfr cells, naïve Foxp3−
TCR-transgenic T cells were transferred into intact re-
cipient mice prior to immunisation. Tfr cells develop
exclusively from recipient cells, whereas Tfh cells devel-
oped from the TCR-transgenic T cells, suggesting Tfr
cells do not derive from Tfh cells [53]. Supporting this,
adoptive transfer of Foxp3+CD4+ or Foxp3−CD4+ cells
into recipient mice showed that Tfr cells derive from
Treg cells and not Foxp3− precursors [44,53] and Tfr
cells do not develop in mice depleted of Treg cells at thetime of immunisation [53]. Moreover, Tfh cells in culture
are resistant to conversion into Foxp3+ cells under Treg
cell polarising conditions [54]. Together, these data indi-
cate that Tfr cells derive from Treg cells rather than
from Tfh cells.
Differentiation and maintenance of follicular regulatory
T cells
Initial experiments using mixed bone marrow chimaeras
showed that Tfr cells require a number of differentiation
cues used in Tfh cell development [53]. Tfr cell develop-
ment requires CD28 and ICOS ligation as well as the
presence of B cells and SAP expression, which facilitates
T:B interactions [53,55]. Like Tfh cells, Tfr cells abso-
lutely require Bcl-6 expression, suggesting that common
developmental cues may be responsible for inducing
their shared transcriptional regulator [44]. In contrast to
Tfh cells, in which Bcl-6 can repress Foxp3 expression,
Tfr cells co-express Bcl-6 and Foxp3. However, the
mechanism by which these transcription factors can be
expressed within the same cell type, and the implications
of this for Tfr cell biology, remain to be demonstrated.
Although Bcl6−/− mice are unable to form Tfr cells [44],
Bcl-6 is not required for the initial upregulation of
CXCR5. In Tfr cells, CXCR5 upregulation depends on
the transcription factor NFAT2 [56]. Strikingly, NFAT2
deficiency in T cells impaired CXCR5 expression by
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sponse. This effect was specific to Tfr cells and Tfh cell
migration was not affected by NFAT2 deficiency. NFAT2
is thus essential to initiate GC homing in Tfr cells, playing
an analogous role to Ascl-2 in Tfh cells. This suggests that
Bcl-6 might be required for stabilising or maintaining Tfr
cell development rather than inducing it.
These data also indicate that, despite their similar
phenotype, Tfh cells and Tfr cells have distinct molecular
regulation of CXCR5 expression and therefore these
cells do not entirely share the same molecular differenti-
ation pathway. Other molecules have been implicated in
Tfr differentiation, such as tumour necrosis factor
receptor-associated factor 3 (TRAF3) [57]. Ablation of
TRAF3 in Foxp3+ Treg cells results in a decrease in the
number of Tfr cells, accompanied by a larger GC re-
sponse and increased antibody production [57]. In con-
trast, expression of the helix–loop–helix proteins Id2
and Id3 in Treg cells represses Tfr cell development, as
mice deficient in these molecules have spontaneous Tfr
cell formation [58]. Together, these data demonstrate
that Tfr cells require specific cues for their formation
from Foxp3+ CD4+ T cells, and if their development is
impaired the GC is larger.
In addition to particular cues being required for their
development, the size of the Tfr cell population is also
controlled at a cell-intrinsic molecular level. In contrast
to Tfh cells, a proportion of Tfr cells express Blimp-1, a
transcription factor important in Treg cell function and
for repressing Tfh cell development [59]. In the absence
of Blimp-1, the Tfr cell population doubles in size, indi-
cating that Bcl-6 and Blimp-1 have reciprocal effects on
Tfr cell numbers, enhancing and reducing the size of the
population, respectively [53]. Tfr cells also have high ex-
pression of the receptor PD-1, an inhibitory molecule
that can dampen lymphocyte responsiveness to antigen
[53,55]. Adoptive transfer experiments using cells from
PD-1-deficient mice showed that PD-1 expression limits
the size of the Tfr cell population [55]. Together, these
experiments demonstrate that Blimp-1 and PD-1 limit
the size of the Tfr cell pool. Tight control of Tfr cell
numbers is likely to be required to ensure appropriate,
and avoid excessive, suppression of the GC.
Follicular regulatory T-cell function
It is tempting to speculate that the absence of Tfr cells
might account for the spontaneous formation of GCs
observed in Foxp3-deficient mice. Consideration of the
kinetics of Tfr and Tfh cell formation argues against
such a role for Tfr cells in controlling the initiation of
the GC. Tfr cells are barely detectable in unimmunised
mice and, after sheep red blood cell immunisation, Tfh
cell numbers peak at days 7 to 11, prior to Tfr cells (days
11 to 17) (Figure 2). This difference demonstrates thatTfr cells are generated in response to immunisation, not
prior to GC induction, and are therefore unlikely to sup-
press the formation of the GC response. The kinetics of
Tfr cell formation suggest that Tfr cells are more likely
to control the function and output of an established GC,
with extrafollicular Treg cells controlling the initiation
of the GC, as discussed earlier in this review.
In vitro Treg cell suppression assays showed that Tfr
cells have a similar suppressive capacity compared with
Treg cells [53]. However, their role in vivo has not been as
easy to dissect. The three initial groups describing Tfr cells
in mice used different experimental strategies to deter-
mine their function in vivo, leading to conflicting results.
In our study, mixed bone marrow chimaeras (SAP-defi-
cient mice and Foxp3-DTR mice) were used to examine
the effect of a specific reduction in Tfr cells on the GC re-
sponse. In this system, immunisation with a T-dependent
antigen significantly increased the number of Tfh cells and
GC B cells, indicating that Tfr cells can suppress features
of the GC response in vivo. When the number of Tfr cells
was reduced, a slight decrease in high-affinity antibodies
was also observed. In addition, antigen-specific GC B cells
were fewer in number, suggesting that Tfr cells can partly
control the GC response by limiting development of non
antigen-specific B cells [53]. In contrast, Chung and col-
leagues used an adoptive transfer model in which Cxcr5−/−
or Bcl6−/− Treg cells together with naïve CD4+ T cells
were transferred into Tcrb−/− mice. An increase in the
number of GC B cells as well as antibody titres of both
high and low affinity could be observed after immunisa-
tion, although the number of Tfh cells was unaffected
[44]. Similar results were obtained in the study by Wollen-
berg and colleagues, in which transfer of Cxcr5−/− Treg
cells into Tcra−/− mice resulted in an increased GC re-
sponse characterised by increased antibody secretion [54].
A later study demonstrated that Tfr cells could suppress
both activation and proliferation of responder T cells and
IgG production in vitro [55].
While these studies agree that Tfr cells can limit the size
of the GC response, whether they also control antigen-
specific antibody production remains contentious. The
discrepancies between these studies may arise from the
use of different immunisation and experimental protocols
undertaken in slightly different environmental conditions.
An additional possible explanation might be the fact that
knocking-out either CXCR5, SAP or Bcl-6 in Treg cells in
these experiments might not affect the Tfr cell population
alone, but may also have an impact on other aspects of
Treg cell biology. New tools will need to be generated to
fully understand the role that Tfr cells play in the GC.
Direct or indirect suppression by follicular regulatory T cells
While it is clear that Tfr cells act to control the size of
the GC response, the mechanism by which they do this
Figure 2 Follicular helper T cells and follicular regulatory T cells have different kinetic profiles. C57BL/6 mice were immunised
intraperitoneally with sheep red blood cells (SRBC) and the numbers of splenic follicular helper T (Tfh) cells and follicular regulatory T (Tfr) cells
were assessed by flow cytometry at different time points. During the germinal centre response, Tfh cells peak slightly earlier compared with Tfr
cells. Tfh cell numbers peak around days 7 to 11 whereas the highest number of Tfr cells can be observed from days 11 to 17.
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or Tfh cells through cell–cell interaction, via cytokine
production, or through a combination of these. Treg
cells can directly inhibit B-cell antibody production
in vitro in a cell contact-dependent manner [60]. Tfr
cells cannot form in the absence of B cells or SAP, sug-
gesting that Tfr cells or Tfr precursor cells interact with
B cells in vivo [53]. Thus, Tfr cells may limit the GC re-
sponse by direct interaction with GC B cells. However,
Treg cells are also able to suppress effector T cells dir-
ectly in vitro [52], so Tfr cells may also act by suppress-
ing the expansion or function of Tfh cells through direct
contact. One key molecule highly expressed by Treg
cells that is implicated in suppression of GC responses is
CTLA-4 [61]. When CTLA-4 signalling is blocked dur-
ing an established GC response, the GC B cells continue
to proliferate and GC resolution is prevented. Further-
more, the direct suppression of B cells in vitro by Treg
cells is partially mediated by CTLA-4 [60]. Thus CTLA-
4, in addition to its role in suppressing the initiation of
the GC response, may also help in mediating Tfr cell
suppression of the GC response.
Tfr cells may also exert their suppressive effects in the
GC indirectly via cytokine secretion. One candidate
would be IL-10, which has an established role in mediat-
ing Treg suppression and is expressed by Tfr cells [16].
Mice with Foxp3+ Treg cells deficient in IL-10 do not
develop severe autoimmunity but do develop spontan-
eous gastrointestinal inflammation [62]. The role of IL-
10 during immune responses is complex and both IL-10
and its receptor (IL-10R) are broadly expressed by differ-
ent immune cell types [63]. IL-10 limits the size of the
population of CD4+CXCR5+ T cells in secondary lymph-
oid organs [64] and seems to be involved in a positive
feedback loop, enhancing its own production by Treg
cells [65]. Because IL-10 deficiency in Foxp3+ Treg cells
does not result in excessive autoantibody formation, it
seems likely that IL-10 production by Tfr cells may playa minor role in controlling Tfh cells rather than mediat-
ing major suppressive effects. Tfr cells are thus likely to
exert their suppressive effect on distinct cell types in the
GC by a number of mechanisms (Figure 3).
Follicular regulatory T cells and their potential role in
autoimmunity
Somatic hypermutation of B-cell immunoglobulin genes
within the GC can potentially generate autoreactive B-cell
clones due to the random nature of the induced point mu-
tations. Elimination of these self-reactive clones from the
GC is therefore important for maintaining immunological
tolerance and preventing autoimmunity [66]. Tfh cells are
an important peripheral tolerance checkpoint within the
GC to ensure that B cells with self-reactive BCRs do not
exit the GC as long lived-plasma cells and memory B cells.
Sanroque mice have aberrant accumulation of Tfh cells
that drive spontaneous GCs and autoimmunity, indicating
that Tfh cells can support self-reactive GCs [67,68].
It is also possible that Tfr cells may contribute to main-
taining GC tolerance as they have been reported to limit
the number of non antigen-specific GC B cells [53] and
they derive from Treg precursors that possess TCRs
skewed towards self-antigens. In support of this hypoth-
esis, intravenous Ig treatment in collagen-induced arthritis
in mice has been shown to reduce pathology and is associ-
ated with increased numbers of Tfr cells and a decrease in
the number of GC B cells [69]. In addition, the importance
of Tfr cells in autoimmune diseases has recently also been
suggested in autoimmune BXD2 mice that are charac-
terised by spontaneous autoreactive GC formation [70].
In BXD2 mice, IL-21 promotes GC formation by selective
expansion of Tfh cells skewing the Tfh/Tfr ratio towards
Tfh cells. Lack of IL-21 in BXD2 mice results in in-
creased numbers of Tfr cells, and, importantly, transfer
of these Tfr cells can decrease GC formation and autoanti-
body production in BXD2 mice [70]. Together, these
data suggest that skewing the Tfh/Tfr balance potentially
Figure 3 Follicular regulatory T cells control the output of the germinal centre response. Direct suppression of germinal centre B cells
might occur through cytotoxic T-lymphocyte antigen 4 (CTLA-4)-mediated inhibition of CD80/CD86 co-stimulatory signalling. Alternatively,
follicular regulatory T (Tfr) cell-mediated suppression may take place in an indirect manner by means of IL-10 secretion acting on follicular
helper T (Tfh) cells. DZ, dark zone; FDC, follicular dendritic cells; LZ, light zone.
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this balance could have therapeutic potential.
Follicular regulatory T cells as a specialised regulatory T-cell
subset
In recent years it has become increasingly clear that, like
CD4+ Th cells, Treg cells are functionally and phenotypic-
ally diverse. Foxp3+ Treg cells can differentiate into several
functional states characterised by expression of specific
transcription factors classically associated with different
Th-cell subsets. For example, during a Th1-skewed re-
sponse, Foxp3+ Treg cells upregulate Tbet in a STAT1-
dependent manner, the key transcription factor for Th1
cell differentiation [71,72]. Tbet expression in Treg cells
drives CXCR3 expression, as it does in Th1 cells, and en-
ables these Th1-like Treg cells to migrate towards the site
of inflammation where they can specifically regulate Th1
responses. The induction of these CXCR3+Tbet+ Treg
cells occurs in an interferon gamma-dependent manner,
similar to Th1 cells [72]. Th17 cell-mediated immune re-
sponses can be specifically controlled by Treg cells ex-
pressing Th17-associated STAT3, as Treg cell-specific
deletion of STAT3 results in fatal intestinal inflammation
and excessive Th17 responses [73]. Tfh cells are the critical
Th cell population for the GC, and Tfr cells phenotypically
resemble Tfh cells in many respects, as described in this
review. Tfr cells thus fit in a model in which Treg cells co-
opt aspects of specific Th cell differentiation pathways, en-
abling them to migrate to sites where these Th cells are
functioning in immune responses. Once there, their sup-
pressive effects help ensure that collateral damage is mini-
mised during the fight against infection.Conclusions
Tfr cells are a subset of Foxp3+ Treg cells that adopt fea-
tures of Tfh cells to enable them to migrate into the GC
while maintaining their suppressive function. These Tfr
cells control the magnitude of the GC response and
form within the GC, whereas extrafollicular Foxp3+ Treg
cells likely regulate the initiation of, and input to, the
GC response. Although it is clear that Tfr cells exert a
suppressive function in the GC, some controversy re-
mains about mechanisms and targets of their suppres-
sion. Further research needs to be done in order to
unravel the exact mechanisms by which Tfr cells sup-
press the GC response, to disentangle the intrafollicular
and extrafollicular roles of Foxp3+ Treg cells and to de-
termine to what extent Tfr cells play a role in the pre-
vention of GC-derived autoimmunity.
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